RU2007111467A - CONTRAST AGENT TARGETED AT THE PLASMINOGEN UROKINASE ACTIVATOR RECEPTOR - Google Patents
CONTRAST AGENT TARGETED AT THE PLASMINOGEN UROKINASE ACTIVATOR RECEPTOR Download PDFInfo
- Publication number
- RU2007111467A RU2007111467A RU2007111467/15A RU2007111467A RU2007111467A RU 2007111467 A RU2007111467 A RU 2007111467A RU 2007111467/15 A RU2007111467/15 A RU 2007111467/15A RU 2007111467 A RU2007111467 A RU 2007111467A RU 2007111467 A RU2007111467 A RU 2007111467A
- Authority
- RU
- Russia
- Prior art keywords
- agent according
- imaging
- visualization agent
- group
- alanine
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title 1
- 108010051456 Plasminogen Proteins 0.000 title 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 title 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 239000002872 contrast media Substances 0.000 title 1
- 229960005356 urokinase Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 238000012800 visualization Methods 0.000 claims 12
- 239000012216 imaging agent Substances 0.000 claims 7
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 5
- 235000004279 alanine Nutrition 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- 229940000635 beta-alanine Drugs 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 238000002059 diagnostic imaging Methods 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 229910044991 metal oxide Inorganic materials 0.000 claims 2
- 150000004706 metal oxides Chemical class 0.000 claims 2
- 238000012634 optical imaging Methods 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 claims 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 238000012879 PET imaging Methods 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 claims 1
- 239000006096 absorbing agent Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000005293 ferrimagnetic effect Effects 0.000 claims 1
- 230000005294 ferromagnetic effect Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000005291 magnetic effect Effects 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000012636 positron electron tomography Methods 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- -1 superparamagnetic Chemical class 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000012285 ultrasound imaging Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (18)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20044139 | 2004-09-29 | ||
NO20044139 | 2004-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007111467A true RU2007111467A (en) | 2008-11-10 |
RU2394837C2 RU2394837C2 (en) | 2010-07-20 |
Family
ID=35930012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007111467/04A RU2394837C2 (en) | 2004-09-29 | 2005-09-28 | Contrast agent aimed at urokinase plasminogen activator receptor |
Country Status (11)
Country | Link |
---|---|
US (1) | US8568689B1 (en) |
EP (1) | EP1796733A2 (en) |
JP (1) | JP5122962B2 (en) |
KR (1) | KR101248350B1 (en) |
CN (1) | CN101065152A (en) |
AU (1) | AU2005287934B2 (en) |
BR (1) | BRPI0516168A (en) |
CA (1) | CA2580464A1 (en) |
MX (1) | MX2007003750A (en) |
RU (1) | RU2394837C2 (en) |
WO (1) | WO2006036071A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070190068A1 (en) * | 2005-10-10 | 2007-08-16 | Richard Hart | uPAR-binding molecule-drug conjugates and uses thereof |
JP2010513476A (en) * | 2006-12-20 | 2010-04-30 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | Contrast agent |
GB0718967D0 (en) * | 2007-09-28 | 2007-11-07 | Ge Healthcare Ltd | Peptide imaging agents |
GB0718957D0 (en) * | 2007-09-28 | 2007-11-07 | Ge Healthcare Ltd | Optical imaging agents |
CN107362376A (en) * | 2010-07-27 | 2017-11-21 | 通用电气健康护理有限公司 | Radiopharmaceutical composition |
WO2013167130A1 (en) * | 2012-05-08 | 2013-11-14 | Rigshospitalet | 177-Lu LABELED PEPTIDE FOR SITE-SPECIFIC uPAR-TARGETING |
WO2014086364A1 (en) | 2012-12-03 | 2014-06-12 | Rigshospitalet | Positron emitting radionuclide labeled peptides for human upar pet imaging |
ES2828954T3 (en) * | 2014-09-17 | 2021-05-28 | Fluoguide As | UPAR Site-Specific Peptide for Use in Perioperative Optical Imaging of Invasive Cancer |
US20210138090A1 (en) * | 2014-09-17 | 2021-05-13 | Fluoguide A/S | uPAR targeting peptide for use in peroperative optical imaging of invasive cancer |
PT3166606T (en) * | 2015-06-03 | 2018-10-01 | Surgimab S A S | Fluorescent conjugates |
EP3759121A1 (en) * | 2018-03-01 | 2021-01-06 | Trigemina, Inc. | Labeled oxytocin and method of manufacture and use |
JP2022544647A (en) * | 2019-07-16 | 2022-10-20 | リグスホスピタレット | Urokinase plasminogen activator receptor targeting peptide |
EP3999123A1 (en) * | 2019-07-16 | 2022-05-25 | Fluoguide A/S | A receptor-targeting conjugate with an effective pharmacokinetic profile |
KR20230173075A (en) | 2020-12-01 | 2023-12-26 | 큐라사이트 에이/에스 | Urokinase Plasminogen Activator Receptor Targeted Radiolabeled Peptide Conjugates |
US20240066142A1 (en) * | 2021-01-15 | 2024-02-29 | Fluoguide A/S | A upar (urokinase plasminogen activator receptor)-targeting conjugate |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6120765A (en) * | 1993-04-02 | 2000-09-19 | Shiseido Co. Ltd. | Urokinase plasminogen activator fragments |
US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
US6277818B1 (en) * | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
GB9705521D0 (en) | 1997-03-18 | 1997-05-07 | Univ Sheffield | The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue |
AR020101A1 (en) * | 1998-07-01 | 2002-04-10 | Cancerforskingsfonden Af 1989 | A PEPTIDE ANTAGONIST OF THE HUMAN UROQUINASE RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING HIM, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND METHODOPARA TO SELECT AN ADEQUATE PEPTIDE ANTAGONIST. |
EP1218496A2 (en) * | 1999-10-01 | 2002-07-03 | Angstrom Pharmaceuticals, inc. | DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
US6896870B1 (en) * | 1999-10-01 | 2005-05-24 | Angstrom Pharmaceuticals, Inc. | Diagnostic probes and therapeutics targeting uPA and uPAR |
ATE447417T1 (en) | 2004-03-04 | 2009-11-15 | Ge Healthcare As | CONJUGATES OF ANGIOTENSIN-PEPTIDE ANALOGAS AND CHELATING AGENTS FOR DIAGNOSIS AND THERAPY |
-
2005
- 2005-09-28 JP JP2007533418A patent/JP5122962B2/en not_active Expired - Fee Related
- 2005-09-28 US US11/576,193 patent/US8568689B1/en not_active Expired - Fee Related
- 2005-09-28 CN CNA2005800408838A patent/CN101065152A/en active Pending
- 2005-09-28 WO PCT/NO2005/000362 patent/WO2006036071A2/en active Application Filing
- 2005-09-28 KR KR1020077007004A patent/KR101248350B1/en not_active IP Right Cessation
- 2005-09-28 RU RU2007111467/04A patent/RU2394837C2/en not_active IP Right Cessation
- 2005-09-28 AU AU2005287934A patent/AU2005287934B2/en not_active Ceased
- 2005-09-28 CA CA002580464A patent/CA2580464A1/en not_active Abandoned
- 2005-09-28 EP EP05788552A patent/EP1796733A2/en not_active Withdrawn
- 2005-09-28 MX MX2007003750A patent/MX2007003750A/en active IP Right Grant
- 2005-09-28 BR BRPI0516168-1A patent/BRPI0516168A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2394837C2 (en) | 2010-07-20 |
CN101065152A (en) | 2007-10-31 |
EP1796733A2 (en) | 2007-06-20 |
WO2006036071A2 (en) | 2006-04-06 |
KR20070083604A (en) | 2007-08-24 |
US8568689B1 (en) | 2013-10-29 |
BRPI0516168A (en) | 2008-08-26 |
MX2007003750A (en) | 2007-11-07 |
AU2005287934B2 (en) | 2009-03-26 |
CA2580464A1 (en) | 2006-04-06 |
AU2005287934A1 (en) | 2006-04-06 |
KR101248350B1 (en) | 2013-04-01 |
JP5122962B2 (en) | 2013-01-16 |
WO2006036071A3 (en) | 2007-02-15 |
JP2008514588A (en) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007111467A (en) | CONTRAST AGENT TARGETED AT THE PLASMINOGEN UROKINASE ACTIVATOR RECEPTOR | |
Helbok et al. | Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals | |
JP2008514588A5 (en) | ||
US8834844B2 (en) | Chemical exchange saturation transfer based MRI using reporter genes and MRI methods related thereto | |
US9284381B2 (en) | Methods and reagents for preparing multifunctional probes | |
JP2020079288A (en) | Malignant tumor-targeting peptides | |
CN105377287A (en) | Kit for tumor imaging | |
US10471162B2 (en) | Collagen targeted imaging probes | |
Ishizaki et al. | Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives | |
EP3166967A1 (en) | Synthetic somatostatin receptor ligands | |
JP2020518656A5 (en) | ||
US9889213B2 (en) | Multimodal imaging of fibrin | |
Franc et al. | Preclinical SPECT and SPECT-CT in oncology | |
US20050118099A1 (en) | Thiol-mediated drug attachment to targeting peptides | |
Sturzu et al. | The gastrin/cholecystokinin-B receptor on prostate cells–a novel target for bifunctional prostate cancer imaging | |
KR102069104B1 (en) | Polypeptide and imaging method | |
Yang et al. | In vitro assessment of the dual-targeting behavior of a peptide-based magnetic resonance imaging contrast agent | |
KR101957416B1 (en) | Targeting compound of cancer and use thereof | |
O'Brien | Self-Assembling Peptide-Based High-Relaxivity Prostate-Cancer-Targeted MRI Contrast Agents | |
ES2846023T3 (en) | Selective glucagon receptor agonists comprising an imaging chelating moiety | |
US9272054B2 (en) | Agents for the molecular imaging of serine-protease in human pathologies | |
Yapıcı et al. | A False Positive Uptake of F-18-Fluorodeoxyglucose in the Liver in PET/CT Scan: Case Report | |
Bhushan et al. | The development of an MR agent for imaging of malignant micro-calcification in breast cancer | |
Lee et al. | Radiolabeling, autoradiogram and in vivo Imaging of atherosclerosis-specific peptide | |
Möllmann | Design of Molecular Ligands for (Nuclear) Imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140929 |